Impact of anemia on short‐term outcomes after <scp>TAVR</scp>: A subgroup analysis from the <scp>BRAVO</scp>‐3 randomized trial
Victor Razuk(Mount Sinai Hospital), George Dangas(Mount Sinai Hospital), Davide Cao(Cardiovascular Institute of the South), Roberto Violini(IRCCS San Camillo Hospital), Samantha Sartori(Icahn School of Medicine at Mount Sinai), Roxana Mehran(Mount Sinai Hospital), Christophe Tron(Université de Rouen Normandie), Raban Jeger(Triemli Hospital), Nicolas Méneveau(Université de Franche-Comté), David Power(Cardiovascular Institute of the South), Prodromos Anthopoulos(Arena Pharmaceuticals (United States)), Pieter R. Stella(University Medical Center Utrecht), Anton Camaj(Columbia University Irving Medical Center), Zhongjie Zhang(Shanxi Medical University), Nicolas Dumonteil(Clinique Pasteur), Johny Nicolas(Cardiovascular Institute of the South), Mauro Chiarito(Humanitas University), Frans Beerkens(Icahn School of Medicine at Mount Sinai), Markus Ferrari(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Julian D. Widder(Städtisches Klinikum Karlsruhe), Christian Hengstenberg(Medical University of Vienna)
Cited by 4
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k